Unichem Laboratories

Unichem Laboratories EBITDA per Share

The EBITDA per Share of Unichem Laboratories (UNICHEMLAB.NS) as of Oct 29, 2026 is 37.55 INR. In the previous year, EBITDA per Share was 3.69 INR — a change of 918.19% (higher).

EBITDA per Share

37.55INR

YoY

918.19%

Last updated:

EBITDA per Share of Unichem Laboratories is 2025 37.55 INR. EBITDA per Share of Unichem Laboratories was 2024 3.69 INR. It decreases by 918.19% higher compared to the previous year.

The Unichem Laboratories EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2018
-18.14 INR
Jan 1, 2019
-10.56 INR
Jan 1, 2020
-7.06 INR
Jan 1, 2021
13.02 INR
Jan 1, 2022
11.07 INR
Jan 1, 2023
-11.24 INR
Jan 1, 2024
3.69 INR
Jan 1, 2025
37.55 INR
The Unichem Laboratories EBITDA per Share history
YEAREBITDA per ShareYoY
37.55INR+918.19%
3.69INR-132.82%
-11.24INR-201.50%
11.07INR-14.99%
13.02INR-284.50%
-7.06INR-33.18%
-10.56INR-41.75%
-18.14INR+214.68%
-5.76INR-125.30%
22.78INR+58.03%
14.42INR-42.93%
25.26INR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Unichem Laboratories Stock analysis

What does Unichem Laboratories do? Unichem Laboratories Ltd. generates revenue through the manufacturing and marketing of pharmaceutical formulations, including branded generics and generics across global markets. The company develops and produces complex active pharmaceutical ingredients (API) and dosage forms, targeting therapeutic areas such as gastroenterology, cardiology, diabetology, psychiatry, neurology, anti-bacterial, anti-infectives, and pain management. Its subsidiaries, Unichem Pharmaceuticals (USA) Inc, Unichem Farmaceutica Do Brasil Lta, and Niche Generics Limited UK, support its international operations. Contract manufacturing services for immediate-release and extended-release dosage forms, dry powder injections, syrups, and novel drug delivery systems also contribute to its revenue streams. The company sells its products to healthcare providers, hospitals, and pharmacies worldwide, leveraging its focus on product development and process chemistry. Unichem Pharmaceuticals (USA) Inc and Unichem Farmaceutica Do Brasil Lta serve as key regional entities for market expansion, while Niche Generics Limited UK facilitates operations in the European market. The firm's portfolio includes both branded generics and generic formulations, catering to diverse therapeutic needs across multiple geographies. Unichem Laboratories Ltd. emphasizes technology transfer and documentation in its contract manufacturing services, which are sought by partners in the pharmaceutical industry. The company's product range addresses critical healthcare segments, ensuring consistent demand for its formulations. Its global presence, supported by subsidiaries in the USA, Brazil, and the UK, enables it to serve international clients effectively. Unichem Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Unichem Laboratories stock

EBITDA per Share of Unichem Laboratories is 37.55 INR in 2025.

EBITDA per Share of Unichem Laboratories changed from 3.69 INR to 37.55 INR, representing a 918.19% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Unichem Laboratories since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Unichem Laboratories

All Key Metrics — Unichem Laboratories